Compare EXFY & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | CVRX |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 139.8M |
| IPO Year | 2021 | 2021 |
| Metric | EXFY | CVRX |
|---|---|---|
| Price | $2.32 | $3.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.50 | ★ $10.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $56,651,000.00 |
| Revenue This Year | $0.42 | $17.17 |
| Revenue Next Year | $0.11 | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.06 | ★ 10.45 |
| 52 Week Low | $0.69 | $2.20 |
| 52 Week High | $2.81 | $11.30 |
| Indicator | EXFY | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 36.00 |
| Support Level | $1.32 | N/A |
| Resistance Level | N/A | $6.06 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 51.42 | 24.21 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.